3 Biotech Stocks With Major 2026 Catalysts

Key Takeaways Denali awaits an April 5, 2026 FDA decision after a BLA review extension for its Hunter syndrome therapy.Nuvalent's zidesamtinib NDA was accepted, with a Sept. 18, 2026 FDA action date in ROS1-positive NSCLC.VNDA seeks priority review for imsidolimab in GPP, which could allow FDA approval as early as mid-2026.The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentim ...